Gossamer Bio, Inc. Common Stock

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Related tickers: GOSS.

Goldman Sachs has decided to maintain its Buy rating of Gossamer Bio (NASDAQ:GOSS) and lower its price target from $9.00 to $8.00. Shares of Gossamer Bio are trading up 0.69% over the last 24 hours, at $1.46 per share. A move to $8.00 would account for a 447.95% increase from the current share price. About Gossamer Bio Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary ...Full story available on Benzinga.com

Related tickers: GOSS.